ForCast Orthopedics, Inc. and KORU Medical Systems, Inc. jointly announced an agreement leveraging KORU Medical’s FreedomEDGE infusion system as part of ForCast’s technology platform for the treatment of periprosthetic joint infection (PJI). PJI is a rare but serious complication of joint replacement procedures, and is challenging to treat because the infecting bacteria adhere to the prothesis and can form a protective biofilm which is resistant to standard systemic antibiotics.
Health Technology Insights: CatalYm Updates Leadership to Boost Visugromab Trials
KORU Medical’s FreedomEDGE pump will provide the infusion technology to support ForCast’s proprietary delivery system for PJI treatment, known as WIIS (Wearable Intra-Articular Infusion System), in anticipation of initiating a clinical trial in 2026.
“We are excited to kick off this development program with KORU,” said Peter Noymer, PhD, Executive Chairman and CEO of ForCast. “After reviewing the entire landscape of infusion pump technologies available, it became clear that KORU’s products were best suited for partnering with our WIIS platform and for meeting the needs of PJI patients.”
Health Technology Insights: Raludotatug Deruxtecan Gets FDA Breakthrough for Ovarian Cancer
ForCast’s lead program, FC001, has received both Orphan Drug Designation and Qualified Infectious Disease Program (QIDP) designation from the US Food & Drug Administration, which enable eligibility for Fast-Track Designation and Priority Review.
“We look forward to working with ForCast and helping them achieve their mission to modernize the standard of care for PJI,” said Linda Tharby, President and CEO of KORU Medical. “Supporting such a novel delivery system highlights the utility of the Freedom System and we are proud to be a trusted supplier for our valued partners.”
Health Technology Insights: Hercules Pharmaceuticals Appoints Elie Bahou as Executive Vice President
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
